**Appendix Table E95. Phenotypic test details in studies assessing the predictive ability of PFA-100 in patients with ischemic heart, cerebrovascular and peripheral vascular disease**

| **Author, year [ref]**  **UID**  **Country**  **Study Name** | **Test/Device name**  **Device category Device name & manufacturer\*** | **Agonist used** | **Sample Collection and Procurement**  **Anticoagulant used**  **Interval between clopidogrel doses and blood sampling (in days)**  **Interval between sampling and testing (in days):** | **Grouping of Phenotypes [Definition]** | **Rational for the grouping of phenotypes reported (Yes/No)**  **[short description]** | **Frequency of phenotypes** |
| --- | --- | --- | --- | --- | --- | --- |
| Reny, 2012{Reny, 2012 18240 /id}  22615340  France and Switzerland  ADRIE | PFA-100  platelet function analyzer  The PFA-100 (Dade Behring, Marburg, Germany) | Collagen and ADP | Blood samples collected after antiplatelet therapy intake  0.105 mol/L sodium citrate (1  vol/9 vol)  3 hrs  NR | CT<190s:  CT>190s | based on literature | <190s: 310  ≥190: 339 |